Nick James, MBBS, PhD, discusses the optimal patients to undergo radiotherapy for localized prostate cancer and his approach to perioperative hormone therapy, along with the ProtecT trial.
Dr. James is Professor of Prostate and Bladder Cancer Research at The Institute of Cancer Research in London.